Medical oncology and tumor pharmacotherapy最新文献

Obituary-Peter Reizenstein MD 悼念Peter Reizenstein医学博士

Medical oncology and tumor pharmacotherapy Pub Date : 1993-12-01 DOI: 10.1007/BF02989669

引用次数: 0

Medical oncology and tumor pharmacotherapy Pub Date : 1993-09-01 DOI: 10.1007/BF02987782

引用次数: 0

Abstract: treatment of patients with myelodysplastic syndromes with G-CSF and erythropoietin 摘要:G-CSF联合促红细胞生成素治疗骨髓增生异常综合征

Medical oncology and tumor pharmacotherapy Pub Date : 1993-03-01 DOI: 10.1007/BF02987772

E. Hellström-Lindberg, G. Birgegard, M. Carlsson, J. Carneskog, I. Dahl, I. Dybedal, G. Grimfors, K. Merk, J. Tangen, I. Winqvist, A. Öst, A. Fasth, G. Juliusson, M. Höglund, S. Grützmeier, E. Sandstrom, G. Saeter

引用次数: 0

Strategies for cytokine utilisation in tumor therapy. 细胞因子在肿瘤治疗中的应用策略。

Medical oncology and tumor pharmacotherapy Pub Date : 1993-01-01 DOI: 10.1007/BF02987769

F Di Pierro, F Cavallo, F Pericle, S Bertini, M Giovarelli, G Forni

引用次数: 6

Interferon treatment of human malignancies--a short review. 干扰素治疗人类恶性肿瘤——一个简短的回顾。

Medical oncology and tumor pharmacotherapy Pub Date : 1993-01-01 DOI: 10.1007/BF02987765

S Einhorn, H Strander

{"title":"Interferon treatment of human malignancies--a short review.","authors":"S Einhorn, H Strander","doi":"10.1007/BF02987765","DOIUrl":"https://doi.org/10.1007/BF02987765","url":null,"abstract":"Interferon (IFN) therapy can induce remissions in human malignancies and has been established as a treatment of choice in several diseases. The clinical effects of IFNs are especially obvious in the treatment of hematological malignancies and virus-associated tumor diseases. Most other types of malignant solid tumors are less likely to respond to IFN as monotherapy and optimal therapeutic schedules are yet to be developed. It is of special interest that combinations of IFNs with other treatment modalities have yielded an increased response rate in several diseases. Several studies on the use of IFN as adjuvant therapy are under way. It is possible, if not likely, that the antitumor effects of IFNs are mediated by different cellular effects in cooperation. These may differ between different malignancies. Mainly based on studies comparing in vitro sensitivity of malignant cells to clinical effects on the same tumor, we suggest that the direct effects of IFNs on the malignant cell are of major importance for the antitumor action of IFN. A deepened insight into the cellular aspects of the antitumor action of these cytokines is a prerequisite for the optimal use of IFNs in the treatment of tumors in man.","PeriodicalId":77257,"journal":{"name":"Medical oncology and tumor pharmacotherapy","volume":"10 1-2","pages":"25-9"},"PeriodicalIF":0.0,"publicationDate":"1993-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02987765","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18512623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 42

Regulation of granulocytosis in inflammatory disease and in leukemia. 炎症性疾病和白血病中粒细胞减少的调节。

Medical oncology and tumor pharmacotherapy Pub Date : 1993-01-01 DOI: 10.1007/BF02987761

P Reizenstein, L Stenke

引用次数: 0

BCG in the treatment of superficial cancer of the bladder: a review. 卡介苗治疗浅表性膀胱癌的研究进展。

Medical oncology and tumor pharmacotherapy Pub Date : 1993-01-01 DOI: 10.1007/BF02987766

S Friberg

引用次数: 8

Lactate dehydrogenase levels during MACOP-B chemotherapy for non-Hodgkin's lymphoma. 非霍奇金淋巴瘤MACOP-B化疗期间乳酸脱氢酶水平。

Medical oncology and tumor pharmacotherapy Pub Date : 1993-01-01 DOI: 10.1007/BF02987775

B McAdam, T Smith, W C Love, M Murphy, P A Daly

{"title":"Lactate dehydrogenase levels during MACOP-B chemotherapy for non-Hodgkin's lymphoma.","authors":"B McAdam, T Smith, W C Love, M Murphy, P A Daly","doi":"10.1007/BF02987775","DOIUrl":"https://doi.org/10.1007/BF02987775","url":null,"abstract":"Lactate dehydrogenase (LD) levels rose consistently during MACOP-B chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma (NHL). Levels peaked at week nine and fell to normal within six weeks of completion of therapy. Isoenzyme patterns, studied prospectively in seven patients, showed a parallel rise in LD1 and LD2 suggesting a source other than tumour tissue for the rise in total LD. In the absence of evidence of myocardial or renal damage, haematopoietic tissue was the most likely source. With no evidence of haemolysis, normal serum levels of vitamin B12 and folate and normal red cell folate, dyserythropoiesis was considered to be the underlying mechanism. A rising mean corpuscular volume further reinforced this suggestion. Intensive use of methotrexate along with co-trimoxazole as prophylaxis against pneumoycystis carinii is considered the most likely cause of marrow dysfunction. Failure to recognise that rising LD levels during such therapy is treatment-related, rather than of tumour origin, may lead to inappropriate change or abandonment of therapy.","PeriodicalId":77257,"journal":{"name":"Medical oncology and tumor pharmacotherapy","volume":"10 3","pages":"95-101"},"PeriodicalIF":0.0,"publicationDate":"1993-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02987775","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18512271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Interleukin-2 and interferon in renal cell carcinoma. 白细胞介素-2和干扰素在肾细胞癌中的作用。

Medical oncology and tumor pharmacotherapy Pub Date : 1993-01-01 DOI: 10.1007/BF02987771

P Wersäll

引用次数: 2

Separation of rare cell subpopulations with the aid of biotin-labelled ligands. 利用生物素标记配体分离稀有细胞亚群。

Medical oncology and tumor pharmacotherapy Pub Date : 1993-01-01 DOI: 10.1007/BF02987768

M Steinitz, A Livoff, S Tamir, T Brenner

引用次数: 1